Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy

被引：0
|
作者：
Fouzia Guestini
Katsuhiko Ono
Minoru Miyashita
Takanori Ishida
Noriaki Ohuchi
Saki Nakagawa
Hisashi Hirakawa
Kentaro Tamaki
Yasuyo Ohi
Yoshiaki Rai
Yasuaki Sagara
Hironobu Sasano
Keely May McNamara
机构：
[1] Tohoku University,
[2] Tohoku Kousai Hospital,undefined
[3] Nahanishi Clinic,undefined
[4] Sagara Hospital,undefined
来源：
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词：
Triple-negative breast cancer; Neoadjuvant chemotherapy; Mechanistic markers; Drug resistance; Residual disease; Outcomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：275 / 288
页数：13
相关论文
共 50 条
  • [1] Impact of Topoisomerase II, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Guestini, Fouzia
    Ono, Katsuhiko
    Miyashita, Minoru
    Ishida, Takanori
    Ohuchi, Noriaki
    Nakagawa, Saki
    Hirakawa, Hisashi
    Tamaki, Kentaro
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yasuaki
    Sasano, Hironobu
    McNamara, Keely May
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 275 - 288
  • [2] Prognostic and predictive impact of Ki67 expression in triple-negative breast cancer
    Wang, W.
    Wu, J.
    Zhu, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 19 - 19
  • [3] Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer
    Li, Haitao
    Han, Xinghua
    Liu, Yingxin
    Liu, Guodong
    Dong, Guomin
    ONCOLOGY LETTERS, 2015, 9 (01) : 149 - 152
  • [4] Prognostic value of Ki67 expression in post-treatment tumors of patients with residual triple-negative breast cancer after neoadjuvant chemotherapy
    Kook, Yoonwon
    Lee, Soo-Young
    Baek, Seung Ho
    Kim, Min Ji
    Kim, Junghyun
    Moon, Sohyun
    Lee, Seung Eun
    Bae, Soong June
    Jeong, Joon
    Lee, Sae Byul
    Ahn, Sung Gwe
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
    Wang, Yihua
    Zong, Beige
    Yu, Yu
    Wang, Yu
    Tang, Zhenrong
    Chen, Rui
    Huang, Man
    Liu, Shengchun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Nishimiya, Hiroshi
    Tanaka, Youko
    Minatani, Naoko
    Kikuchi, Mariko
    Shida, Akiko
    Waraya, Mina
    Katoh, Hiroshi
    Enomoto, Takumo
    Sengoku, Norihiko
    Kajita, Sabine
    Hoffman, Robert M.
    Watanabe, Masahiko
    PLOS ONE, 2016, 11 (12):
  • [7] BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Sengoku, Norihiko
    Waraya, Mina
    Nishimiya, Hiroshi
    Katoh, Hirozhi
    Kikuchi, Mariko
    Minatani, Naoko
    Teraoka, Saeko
    Enomoto, Takumo
    Sato, Takeo
    Masahiko, Masahiko
    CANCER RESEARCH, 2015, 75
  • [8] Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67
    Shinichiro Kashiwagi
    Masakazu Yashiro
    Tsutomu Takashima
    Naoki Aomatsu
    Katsumi Ikeda
    Yoshinari Ogawa
    Tetsuro Ishikawa
    Kosei Hirakawa
    Breast Cancer Research, 13
  • [9] Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67
    Kashiwagi, Shinichiro
    Yashiro, Masakazu
    Takashima, Tsutomu
    Aomatsu, Naoki
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Ishikawa, Tetsuro
    Hirakawa, Kosei
    BREAST CANCER RESEARCH, 2011, 13 (06)
  • [10] MRP1 but not MDR1 is associated with response to neoadjuvant chemotherapy in breast cancer patients
    Taheri, Mohsen
    Mahjoubi, Frouzandeh
    DISEASE MARKERS, 2013, 34 (06) : 387 - 393
12345